Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
(
2 selected
)
Type
Guidance (374)
NICE advice (1)
Quality standard (9)
Guidance programme
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (9)
Health technology evaluations (11)
Highly specialised technologies guidance (8)
Interventional procedures guidance (15)
Medical technologies guidance (13)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (296)
Apply filters
Showing 1 to 25 of 383
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Type: Quality standard
Remove Type: Quality standard filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]
Technology appraisal guidance
TBC
Abaloparatide for treating osteoporosis in postmenopausal women [ID882]
Technology appraisal guidance
TBC
Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]
Technology appraisal guidance
TBC
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]
Technology appraisal guidance
TBC
Abicipar pegol for treating wet age-related macular degeneration ID1533
Technology appraisal guidance
TBC
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Technology appraisal guidance
TBC
Acute kidney injury: prevention, detection and management - Assessing risk factors for acute kidney injury in adults having iodine-based contrast media
NICE guideline
16 October 2024
Adrenal insufficiency: identification and management
NICE guideline
28 August 2024
Alcohol-mediated perivascular renal denervation for resistant hypertension
Interventional procedures guidance
5 February 2025
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]
Technology appraisal guidance
11 December 2024
ALXN1840 for treating Wilson disease TS ID 9950
Technology appraisal guidance
TBC
Alzheimer's disease (early) - gantenerumab [ID6142]
Technology appraisal guidance
TBC
Amyotrophic lateral sclerosis - SAR443820 [ID6386]
Technology appraisal guidance
TBC
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]
Technology appraisal guidance
18 December 2024
Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]
Technology appraisal guidance
TBC
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]
Technology appraisal guidance
TBC
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]
Highly specialised technology
TBC
Artificial intelligence (AI) technologies for assessing skin lesions referred on the urgent suspected cancer pathway
Health technology evaluation
TBC
Artificial intelligence software to help detect fractures in the emergency department (provisional title)
Health technology evaluation
17 December 2024
Asthma: diagnosis, monitoring and chronic asthma management
NICE guideline
30 October 2024
Asunercept for treating glioblastoma [1301]
Technology appraisal guidance
TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701
Technology appraisal guidance
TBC
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]
Technology appraisal guidance
TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
Technology appraisal guidance
TBC
Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable ID6218
Technology appraisal guidance
TBC
Current page
1
2
3
…
16
Page
1
of
16
Next page
Results per page
10
25
50
All
Back to top